

GenFleet Therapeutics (Shanghai) Inc.
(勁方醫藥科技(上海)股份有限公司)
Floors 2, 3, 4, and 5, Building 8
1206 Zhangjiang Road
(Shanghai) Pilot Free Trade Zone
PRC

CITIC Securities (Hong Kong) Limited
18/F, One Pacific Place
88 Queensway
Hong Kong
as the Sole Sponsor and

CLSA Limited
18/F, One Pacific Place
88 Queensway
Hong Kong

as the representative of the Hong Kong underwriters listed in Schedule 2 to the Hong Kong Underwriting Agreement (as defined below) and the international underwriters listed in Schedule I to the International Underwriting Agreement (as defined below) (collectively, the "Underwriters")

September 11, 2025

Re: GenFleet Therapeutics (Shanghai) Inc.
(勁方醫藥科技(上海)股份有限公司)

Ladies and Gentlemen:

We are qualified European and German Patent Attorney and German lawyers and as such are qualified to issue this opinion based on the laws of the European Patent Convention and the national Patent Laws of its Contracting States. GenFleet Therapeutics (Shanghai) Inc. (together with its subsidiaries, collectively referred to as the "Company") has requested us to conduct a due diligence review on certain patent matters regarding the Company. We are providing this letter pursuant to Clause 2 of the Hong Kong Underwriting Agreement dated September 10, 2025 (the "Hong Kong Underwriting Agreement") between the Company and the Hong Kong Underwriters and Section 8 of the International Underwriting Agreement dated on or around September 17, 2025 (the "International Underwriting Agreement", together with the Hong Kong Underwriting Agreement, the "Underwriting

2K - Patent- und Rechtsanwälte- München
Straus & Saffer PartmbB (PR 2064)

German Patent Attorneys ¹
European Patent Attorneys ²
European Trademark and
Design Attorneys ³
Swiss Patent Attorney ⁴
Rechtsanwalt / Attorney at Law ⁵
Senior Consultant ¹¹

Dr. Alexander Straus ^{1 2 3 6 8}
Dr.-Phil., Dipl.-Chem

Rainer Saffer ^{2 3 5 6 8}
Rechtsanwalt

Dr. Roman Léandre Vuille ^{2 3 4 8 10}
Dr. Chem.

Dr. Tilo Blasberg ^{1 2 3 7}
Dipl.-Phys.

Ansgar Kewitz ^{1 2 3 7}
Dipl.-Inf.

Johannes Schultenkämper ^{2 3 7}
Dipl.-Ing.

Dr. Ulrich Harbach ^{1 2 3 7}
Dipl.-Phys.

Wolfgang Reichel ^{1 2 3 7}
Dipl.-Ing. – Of Counsel

Prof. Dr.Dr. h.c.mult. Joseph Straus ^{6 11 10}
Prof. of Law

Graham Lock ^{2 3 9}
B.Sc Biochemistry

Heather Donald ^{2 5 9}
LLB, LPC, LLM

Michele Richards ^{2 3 9}
B.Sci Pharmacology

Joel Wenger ^{2 3 4 10}
Dr. Phys

Bankverbindung:
Bank Details:

2K Patent- und Rechtsanwälte - München

EUR Accounts:

HypoVereinsbank:
SWIFT CODE: HYVEDEMM448
IBAN: DE35 7112 0077 0346 8728 10

Deutsche Bank:
SWIFT CODE: DEUTDEMMXXX
IBAN: DE38 7007 0024 0656 8547 00

USD Account:

HypoVereinsbank
SWIFT CODE: HYVEDEMM448
IBAN: DE27 7112 0077 0029 8780 21

VAT Nr. DE 327679784

Büro München (D) ⁶
Büro Frankfurt (D) ⁷
Büro Wien (AT) ⁸
Kooperationsbüro London (UK) ⁹
Kooperationsbüro Eclubens (CH) ¹⁰

straus@2k-muenchen.de
office-straus@2K-muenchen.de
www.2kpatent.de

Tel. +49 (0)89 954 28 368 – 0
Fax. +49 (0)89 954 28 368 – 1

Agreements”) between the Company and the International Underwriters, each in connection with the proposed initial public offering of the Company in the Hong Kong Stock Exchange (the “Offering”). We act as special patent counsel to the Company as to the laws of the European Patent Convention and the national Patent Laws of its Contracting States and our representation has been limited to matters individually referred to us by the Company. There may be patent and related matters involving or impacting the Company of which we are unaware.

In connection with this opinion, we have reviewed the statements included in the Prospectus (the “Disclosure Documents”) related to the patents and patent applications listed in Appendix I attached hereto (the “Company Patents”), which are made in the section titled “Summary” under the heading “Intellectual Property Rights”, and the section titled “Business” under the heading “Intellectual Property” (collectively, the “Patent Statements”). Except with respect to the Patent Statements, we did not participate in the preparation of the Disclosure Documents, and we have not been consulted to advise on any other part of the Disclosure Documents. We have limited our review of the Disclosure Documents to the Patent Statements.

The purpose of our professional engagement was not to establish or confirm factual matters set forth in the Prospectus, and we have not undertaken any obligation to verify those factual matters. Accordingly, except to the extent of our opinions set forth in paragraphs A to H below, we are not passing upon and we assume no responsibility for the accuracy, completeness or fairness of the statements contained in or incorporated by reference into the Disclosure Documents.

Based on the foregoing and all information available by September 2, 2025, and subject to the assumptions, qualifications, limitations and exceptions as stated in this letter, we advise you that:

- A. Nothing has come to our attention causing us to believe that any of the Patent Statements contains any untrue statement of material fact or fails to state any material fact necessary to make the statements therein not misleading, and, to our knowledge, all such statements are accurate and complete and present fairly the information therein.
- B. The Company owns or otherwise possesses sufficient and unrestricted rights under all intellectual property rights that are currently employed by the Company in connection with their respective businesses, or that is necessary for the manufacture, importation, use, or sale of its product candidates as described in the Disclosure Documents. We have not become aware of any facts causing us to believe that the Company does not own the Company Patents described as being owned by them as described in the Disclosure Documents.
- C. To our knowledge, the Company has not in respect of any patent received any notice of infringement of or conflict with any patent rights of others which, in either case, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company.
- D. To our knowledge, there is no claim, action, suit or proceeding pending or threatened against the Company alleging that the Company has infringed, misappropriated or otherwise violated any intellectual property rights of any third party in a Contracting State of the European Patent Convention (“EPC”). We have not become aware of any facts causing us to believe that the current or planned development and commercialization of the Company’s product candidates, as described in the Disclosure Documents, would infringe any issued patents of any third party that, in our opinion, are valid and enforceable. To our knowledge, the Company has not, in respect of any patent, received any notice of infringement of or conflict with any patent rights of others which, in either case, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company.

- E. To our knowledge, no claim, action, suit or proceeding (including any interference, post grant reexamination, derivation, *inter partes* review, post grant review, opposition or other judicial or administrative proceeding) pertaining to the validity, enforceability or scope of any of the Company Patents has been threatened or declared.
- F. To our knowledge, there are no liens, encumbrances or security interests against any Company Patents.
- G. To our knowledge, all applicable fees and surcharges and administrative procedures in relation to the maintenance of the Company Patents have been duly and properly paid and proceeded.
- H. We have not become aware of any facts causing us to believe that the claims of the issued, unexpired patents included in the Company Patents are invalid or unenforceable under the laws of the European Patent Convention and the national Patent Laws of its Contracting States.

The opinions expressed herein are also subject to the following assumptions, limitations, qualifications and exceptions:


- (a) As to matters of fact, we have assumed the authenticity and validity of all records furnished to us by the Company and the information and certificates from various public officials, and we have not made any independent investigation or verification of the authenticity and validity of such records, information and certificates.
- (b) Whenever our opinions herein are qualified by the phrase "to our knowledge", or "known to us" or similar phrases, the relevant knowledge is limited to the current actual knowledge after due and careful inquiry of those attorneys presently in our firm who have performed substantive legal services for the Company in connection with this opinion.
- (c) Except for the issuance of a separate intellectual property due diligence report on December 21st, 2024 and our investigation in connection therewith, and except for our discussions with the Company and our review of documents provided by the Company in connection with this Offering, we have not made any independent investigation with respect to the legal status of the Company Patents, whether any of the Company Patents covers the Company's product candidates as described in the Disclosure Documents, whether the pending claims that cover the Company's relevant product candidates in the patent applications of the Company Patents are assured to be granted, and whether any third-party intellectual property rights constitute a hindrance for the manufacture, importation, use, or sale of the Company's product candidates as described in the Disclosure Documents.
- (d) The opinions expressed herein represent our reasonable judgment as to the matter of law addressed herein, based upon the facts presented, and are not, and shall not be construed as, a guarantee.
- (e) In acting as patent counsel to the Company as to the laws of the European Patent Convention and the national Patent Laws of its Contracting States, we have not been involved with the prosecution of the Company Patents. Any opinions set forth in this letter are limited to the patent laws of the People's Republic of China and the patent laws of the United States, to the extent that the same may apply to or govern such matters addressed herein.

This letter is provided to the Company, the Sole Sponsor and CLSA Limited (in its capacity as the representative of the Underwriters under the Underwriting Agreements) and is solely for your benefit in connection with the Offering. This opinion may not be relied upon by you for any other purpose. This opinion may also not be provided to or relied upon by any other person or entity for any purpose, including, without limitation, any person or entity that acquires any securities of the Company from any of the Underwriters without our prior written consent, which we may withhold at our sole discretion. Notwithstanding these limitations, this letter can properly be furnished to others (i) for the purpose of responding to requests to review this letter by governmental, regulatory or judicial authorities (including the Hong Kong Stock Exchange, the Securities and Futures Commission of Hong Kong and the China Securities Regulatory Commission) having competent jurisdiction over you and (ii) in connection with the defense of any legal or regulatory proceeding or investigation arising out of the Offering, *provided* that 2K Patent- und Rechtsanwälte - München is given written notice in advance to the extent permitted by applicable laws.


This letter is limited to the matters expressly set forth herein, and no opinion has been implied, or may be inferred, beyond the matters expressly stated.

This letter is based on the law and facts as of the date hereof and we undertake no obligation or responsibility to update or supplement this letter to reflect any facts, circumstances, or changes in the law that may later occur or come to our attention.

Very truly yours,



Dr. Alexander Straus

 Patent- und Rechtsanwälte - München

Dr. A. Straus
2K Patentanwälte - München
Bajuwarenring 14
D-82041 Oberhaching/München
Tel.: +49 89 954 28 368-0 Fax: +49 89 954 28 368-1
e-mail: office-straus@2K-muenchen.de

APPENDIX I

Patents of The Company Relating to GF-105 (GFH925) in Europe at the EPO Level (status as of September 2, 2025)

Product	Name of Patent Family	Jurisdiction	Status	Filing Date	Grant Date	Patent Expiration Date	Type	Owner/Applicant	Inventor
GFH925	Substituted Heterocyclic Fused Cyclic Compound, Preparation Method Therefor and Pharmaceutical Use Thereof	EP	Granted	2020-10-28	2024-10-09	2040-10-28	Invention	GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Fusheng Zhou, Tao Jiang, Chonglan Lin, Lijian Cai, Wan He, Jiong Lan
		EP	Pending	2020-10-28	-	-	Invention		
GFH925	Polymorph of KRAS Inhibitor, Preparation Method Therefor, and Use Thereof	EP	Pending	2022-12-23	-	-	Invention	GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Fusheng Zhou, Jinzhu Zhao, Yudong Cao, Lun Xiong, Rongzhen Shi, Jiong

									Lan
GFH925	Pharmaceutical Composition, Use Thereof, and Method for Treating Cancer	EP	Pending	2023- 03-31	-	-	Invention	GENFLEET THERAPEUTICS (SHANGHAI) INC.; ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.	Lili Tang, Xiang Yu, Jingyang Zhang, Huizhong Hu, Fusheng Zhou, Yu Wang, Jiong Lan, Qiang Lu